Durable remissions of AML patients who were treated with venetoclax (a selective BCL2 inhibitor) and azacitidine (a hypomethylating agent) were linked to inhibition of electron transport chain (ETC) complex II and hence OXPHOS suppression which preferentially targeted LSCs [32]. Here, BCL2 is linked to acute myeloid leukemia.